ChiCTR2100046426 版本V1.3 版本创建时间2021/12/16 16:47:19 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100046426 

最近更新日期:

Date of Last Refreshed on:

2021-05-24 23:05:41 

注册时间:

Date of Registration:

2021-05-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

毫火针治疗急性期带状疱疹中火针针刺痛与镇痛作用的相关性研究

Public title:

Study on the correlation between fire-needle pain and analgesic effect in treating acute herpes zoster

注册题目简写:

English Acronym:

研究课题的正式科学名称:

毫火针治疗急性期带状疱疹中火针针刺痛与镇痛作用的相关性研究

Scientific title:

Study on the correlation between fire-needle pain and analgesic effect in treating acute herpes zoster

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2100004853

申请注册联系人:

高宁 

研究负责人:

郭玉峰 

Applicant:

Ning Gao 

Study leader:

Yufeng Guo 

申请注册联系人电话:

Applicant telephone:

86-13842870709

研究负责人电话:

Study leader's
telephone:

18511664134

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nicolegao0709@163.com

研究负责人电子邮件:

Study leader's E-mail:

gamgyf@139.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区北线阁5号广安门医院

研究负责人通讯地址:

北京市西城区北线阁5号广安门医院

Applicant address:

Guang 'anmen Hospital, No.5 Beixiange Street, Xicheng District, Beijing, China

Study leader's address:

Guang 'anmen Hospital, No.5 Beixiange Street, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院广安门医院

Applicant's institution:

Guang 'anmen Hospital, China Academy of Traditional Chinese Medicine

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-037-KY

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院广安门医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guang 'anmen Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2021-03-22 00:00:00

伦理委员会联系人:

乔洁

Contact Name of the ethic committee:

Jie Qiao

伦理委员会联系地址:

北京市西城区北线阁5号广安门医院

Contact Address of the ethic committee:

Guang 'anmen Hospital, No.5 Beixiange Street, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院广安门医院南区

Primary sponsor:

South district of Guang 'anmen Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市黄村镇兴丰大街(二段)138号

Primary sponsor's address:

No.138, Xingfeng Street (Section 2), Huangcun Town, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院南区

具体地址:

黄村镇兴丰大街(二段)138号

Institution
hospital:

South District of Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Address:

138 Second Section of Xingfeng Street, Huangcun Town

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院

具体地址:

西城区北线阁5号广安门医院

Institution
hospital:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Address:

5 Beixian'ge Street, Xicheng District

经费或物资来源:

北京市中医药科技发展资金项目一般规划项目资助以及中国中医科学院广安门医院南区科研业务费资助。

Source(s) of funding:

Supported by the general planning project of Beijing traditional Chinese medicine science and technology development fund and the scientific research business of south district of guang'anmen hospital

研究疾病:

带状疱疹急性期  

Target disease:

Acute herps zoster

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价毫火针结合复方利多卡因乳膏与毫火针结合安慰剂乳膏相比,对急性期带状疱疹的疗效,并在此基础上初步判断毫火针针刺造成的疼痛与毫火针发挥镇痛作用的相关性。  

Objectives of Study:

To compare the effect of fire-needle plus topical compound lidocaine cream and fire-needle plus placebo cream for acute herpes zoster. Then on the basis of the outcomes, We attemp to preliminarily verify the hypothesis fire-needle induced pain is positively correlated with the analgesic effect of fire-needle for neuralgia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合带状疱疹诊断标准;
(2)年龄范围18~75岁;
(3)1周内未服用或外用过抗病毒药物和镇痛药物;
(4)神经病理性疼痛vas值≥50% ;
(5)签署知情同意书,自愿参加本项研究者。

Inclusion criteria

(1) Meeting the diagnostic criteria for herpes zoster;
(2) Age range from 18 to 75 years old;
(3) No antiviral drugs or analgesics have been taken or used topically within one week;
(4) VAS value of neuralgia ≥50%;
(5) Signed the informed consent and volunteered to participate in the study.

排除标准:

(1)特殊类型,如脑膜带状疱疹,内脏带状疱疹,眼、耳带状疱疹,泛发性带状疱疹,无疹型带状疱疹等;
(2)对酰胺类局部麻醉药或对复方利多卡因乳膏中任何其它成份高度过敏者;
(3)长期应用皮质类固醇或免疫抑制剂者;
(4)先天性或特发性高铁血红蛋白血症患者;
(5)哺乳、妊娠或正准备妊娠的妇女;
(6)合并心脑血管、肝、肾、造血系统等严重原发性疾病或全身衰竭者,特异反应性皮炎患者,精神病患者,血友病患者,有出血倾向的患者;
(7)病情危重,难以对治疗的有效性和安全性作出确切评价者;
(8)瘢痕体质者。

Exclusion criteria:

(1) Special types, such as meningeal herpes zoster, visceral herpes zoster, herpes zoster on eyes or ears, generalized herpes zoster, herpes zoster with no rash, etc.;
(2) Highly allergic to amide topical anesthetics or to any other component of compound lidocaine cream;
(3) Long-term use of corticosteroids or immunosuppressants;
(4) Congenital or idiopathic patients with methemoglobinemia;
(5) Women who are in breastfeeding, pregnant or preparing for fetation;
(6) Patients with serious primary diseases or failure with multiple organ(e.g., cardiovascular and cerebrovascular diseases, liver, kidney and hematopoietic system), patients with atopic dermatitis, patients with mental illness, hemophilia and patients with bleeding tendency;
(7) Patients with critical condition who are difficult to accurately evaluate the efficacy and safety of treatment;
(8) Scar diathesis.

研究实施时间:

Study execute time:

From 2020-10-22 00:00:00 To 2022-09-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-05-15 00:00:00 To 2022-03-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

46

Group:

experimental group

Sample size:

干预措施:

火针加复方利多卡因乳膏

干预措施代码:

Intervention:

fire-needle plus topical compound lidocaine cream

Intervention code:

组别:

对照组

样本量:

46

Group:

control group

Sample size:

干预措施:

火针结合安慰剂乳膏

干预措施代码:

Intervention:

fire-needle plus topical placebo cream

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院 

单位级别:

三级甲等 

Institution
hospital:

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院广安门医院南区 

单位级别:

三级甲等 

Institution
hospital:

South District of Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

局部带状疱疹急性神经痛最痛程度VAS评分较基线的变化值

指标类型:

主要指标

Outcome:

The change of the VAS score from baseline in the most painful degree of acute neuralgia in local herpes zoster

Type:

Primary indicator

测量时间点:

治疗8次后

测量方法:

Measure time point of outcome:

After 8 treatments

Measure method:

指标中文名:

带状疱疹急性神经痛最痛VAS评分恒定减少至30%以下所需的时间

指标类型:

次要指标

Outcome:

The time required for constant pain intensity of VAS below 30%

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

带状疱疹急性神经痛最痛VAS评分恒定减少至30%以下患者的百分比

指标类型:

次要指标

Outcome:

Percentage of patients with the most painful VAS score of herpes zoster acute neuralgia decreased to less than 30%

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

venous blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与试验的第三方由SAS软件生成区组随机数字,以4为一个区组,按患者就诊顺序作为分组,具体程序如下:PROC PLAN SEED=20210506; FACTORS block=23 length=4; OUTPUT OUT=rand; RUN; DATA rand; SET rand; number=_n_92; IF length<=2 THEN group="A"; ELSE group="B"; RUN; PROC PRINT NOOBS; VAR block.number group; RUN;

Randomization Procedure (please state who generates the random number sequence and by what method):

A third party, who does not participate in the trial, will generate the block random numbers via the SAS software. Taking 4 as a block group and grouping according to the sequential order of patients' visit. The detailed procedure is as follows:PROC PLAN SEED=20210506; FACTORS block=23 length=4; &#

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年3月,中医局科研网络平台或通过同行评审出版物或相关会议报告进行传播。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

March,2023,the results of the trial will be disseminated via peer-reviewed publication or a relevant conference report.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表;电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-05-15 10:16:25